All Updates

All Updates

icon
Filter
Funding
Quris raises USD 19 million in seed funding
AI Drug Discovery
Jan 11, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 11, 2022

Quris raises USD 19 million in seed funding

Funding

<ul><li> Israeli AI drug discovery company Quris has raised USD 19 million—in addition to the initial USD 9 million seed funding raised in October 2021—in a seed funding round, totaling USD 28 million. The round was led by Welltech Ventures, with participation from iAngels, GlenRock Capital, and other investors.</ul>

  • The proceeds will be directed toward accelerating the research and development of novel therapeutics, growing its team, and entering into synergistic partnerships. The funds will also be used to test the first 100 or 1000 drugs to train the AI platform.

  • Having publicly launched its clinical-prediction AI platform last year, Quris plans to advance the first drug—to treat fragile X syndrome (FXS)—developed on the platform, toward clinical testing in 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.